CisThera Inc. is focused on developing innovative therapeutics aimed at treating a range of serious health conditions, including cancer, autoimmune diseases, and chronic kidney and liver diseases. The company employs a novel approach to drug discovery, concentrating on identifying compounds that demonstrate greater efficacy by broadly inhibiting key contributors to the underlying mechanisms of these diseases. This strategy reflects a commitment to advancing treatment options that can significantly impact patient outcomes.

In its research and development efforts, CisThera emphasizes the importance of targeting validated pathways involved in disease pathogenesis. By leveraging a deep understanding of the biological processes that drive these conditions, the company aims to create therapeutics that not only address symptoms but also tackle the root causes of diseases. This innovative approach positions CisThera at the forefront of biopharmaceutical advancements, with the potential to deliver transformative therapies to patients in need.

United States

CisThera Inc. is a privately owned biopharmaceutical company in the Seattle area.  CisThera’s mission is to develop innovative therapeutics to treat  cancer, autoimmune diseases, as well as chronic kidney and liver diseases.  CisThera is taking a novel approach to identify drugs with greater efficacy that broadly inhibit validated contributors to disease pathogenesis.

Cisthera

Company Details